Olga LenÄovÃ¡

List of Publications by Year
in descending order

35 papers	1,735 citations	393982 19 h-index	395343 33 g-index
36 all docs	36 docs citations	36 times ranked	2483 citing authors

#	Article	IF	Citations
1	Primary prevention of chronic anthracycline cardiotoxicity with ACE inhibitor is temporarily effective in rabbits, but benefits wane in post-treatment follow-up. Clinical Science, 2022, 136, 139-161.	1.8	1
2	Development of water-soluble prodrugs of the bisdioxopiperazine topoisomerase IIÎ² inhibitor ICRF-193 as potential cardioprotective agents against anthracycline cardiotoxicity. Scientific Reports, 2021, 11, 4456.	1.6	6
3	Prodrug of ICRF-193 provides promising protective effects against chronic anthracycline cardiotoxicity in a rabbit model<i>in vivo</i>. Clinical Science, 2021, 135, 1897-1914.	1.8	8
4	Clinically Translatable Prevention of Anthracycline Cardiotoxicity by Dexrazoxane Is Mediated by Topoisomerase II Beta and Not Metal Chelation. Circulation: Heart Failure, 2021, 14, e008209.	1.6	24
5	Investigation of Structure-Activity Relationships of Dexrazoxane Analogs Reveals Topoisomerase II<i>Î²</i>Interaction as a Prerequisite for Effective Protection against Anthracycline Cardiotoxicity. Journal of Pharmacology and Experimental Therapeutics, 2020, 373, 402-415.	1.3	14
6	<i>In vitro</i> and <i>in vivo</i> investigation of cardiotoxicity associated with anticancer proteasome inhibitors and their combination with anthracycline. Clinical Science, 2019, 133, 1827-1844.	1.8	10
7	79â€...Effective cardioprotection against anthracycline cardiotoxicity in isolated cardiomyocytes and rabbits is based on dexrazoxane interaction with topoisomerase II beta instead of iron chelation by its metabolite ADR-925. , 2019, , .		0
8	Pharmacokinetics of the Cardioprotective Drug Dexrazoxane and Its Active Metabolite ADR-925 with Focus on Cardiomyocytes and the Heart. Journal of Pharmacology and Experimental Therapeutics, 2018, 364, 433-446.	1.3	15
9	Are cardioprotective effects of NO-releasing drug molsidomine translatable to chronic anthracycline cardiotoxicity settings?. Toxicology, 2016, 372, 52-63.	2.0	1
10	Cardioprotective effects of inorganic nitrate/nitrite in chronic anthracycline cardiotoxicity: Comparison with dexrazoxane. Journal of Molecular and Cellular Cardiology, 2016, 91, 92-103.	0.9	20
11	Synthesis and analysis of novel analogues of dexrazoxane and its open-ring hydrolysis product for protection against anthracycline cardiotoxicity in vitro and in vivo. Toxicology Research, 2015, 4, 1098-1114.	0.9	20
12	Proteomic investigation of embryonic rat heart-derived H9c2 cell line sheds new light on the molecular phenotype of the popular cell model. Experimental Cell Research, 2015, 339, 174-186.	1.2	13
13	Experimental determination of diagnostic window of cardiac troponins in the development of chronic anthracycline cardiotoxicity and estimation of its predictive value. International Journal of Cardiology, 2015, 201, 358-367.	0.8	9
14	ANTHRACYCLINE CARDIOTOXICITY: THE PHARMACOKINETICS AND PHARMACODYNAMICS OF DEXRAZOXANE AND ITS OPEN RING METABOLITE. Heart, 2014, 100, A7.1-A7.	1.2	0
15	Molecular Remodeling of Left and Right Ventricular Myocardium in Chronic Anthracycline Cardiotoxicity and Post-Treatment Follow Up. PLoS ONE, 2014, 9, e96055.	1.1	38
16	Early and delayed cardioprotective intervention with dexrazoxane each show different potential for prevention of chronic anthracycline cardiotoxicity in rabbits. Toxicology, 2013, 311, 191-204.	2.0	28
17	Oxidative Stress, Redox Signaling, and Metal Chelation in Anthracycline Cardiotoxicity and Pharmacological Cardioprotection. Antioxidants and Redox Signaling, 2013, 18, 899-929.	2.5	267
18	Chronic Anthracycline Cardiotoxicity: Molecular and Functional Analysis with Focus on Nuclear Factor Erythroid 2-Related Factor 2 and Mitochondrial Biogenesis Pathways. Journal of Pharmacology and Experimental Therapeutics, 2012, 343, 468-478.	1.3	48

#	Article	IF	Citations
19	Protective effects of dexrazoxane against acute ischaemia/reperfusion injury of rat hearts. Canadian Journal of Physiology and Pharmacology, 2012, 90, 1303-1310.	0.7	16
20	Proteomic insights into chronic anthracycline cardiotoxicity. Journal of Molecular and Cellular Cardiology, 2011, 50, 849-862.	0.9	57
21	In vivo and in vitro assessment of the role of glutathione antioxidant system in anthracycline-induced cardiotoxicity. Archives of Toxicology, 2011, 85, 525-535.	1.9	24
22	Comparison of Clinically Used and Experimental Iron Chelators for Protection against Oxidative Stress-Induced Cellular Injury. Chemical Research in Toxicology, 2010, 23, 1105-1114.	1.7	61
23	Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death. British Journal of Cancer, 2009, 101, 792-802.	2.9	53
24	Anthracycline-induced cardiotoxicity: Overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacological Reports, 2009, 61, 154-171.	1.5	633
25	Anthracycline toxicity to cardiomyocytes or cancer cells is differently affected by iron chelation with salicylaldehyde isonicotinoyl hydrazone. British Journal of Pharmacology, 2008, 155, 138-148.	2.7	42
26	Pyridoxal Isonicotinoyl Hydrazone (PIH) and its Analogs as Protectants Against Anthracycline-Induced Cardiotoxicity. Hemoglobin, 2008, 32, 207-215.	0.4	8
27	Deferiprone Does Not Protect against Chronic Anthracycline Cardiotoxicity in Vivo. Journal of Pharmacology and Experimental Therapeutics, 2008, 326, 259-269.	1.3	43
28	Iron chelation-afforded cardioprotection against chronic anthracycline cardiotoxicity: A study of salicylaldehyde isonicotinoyl hydrazone (SIH). Toxicology, 2007, 235, 150-166.	2.0	32
29	New iron chelators in anthracycline-induced cardiotoxicity. Cardiovascular Toxicology, 2007, 7, 145-150.	1.1	30
30	In vitro and in vivo examination of cardiac troponins as biochemical markers of drug-induced cardiotoxicity. Toxicology, 2007, 237, 218-228.	2.0	55
31	Cardioprotective Effects of a Novel Iron Chelator, Pyridoxal 2-Chlorobenzoyl Hydrazone, in the Rabbit Model of Daunorubicin-Induced Cardiotoxicity. Journal of Pharmacology and Experimental Therapeutics, 2006, 319, 1336-1347.	1.3	40
32	HPLC determination of a novel aroylhydrazone iron chelator (o-108) in rabbit plasma and its application to a pilot pharmacokinetic study. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2006, 838, 107-112.	1.2	14
33	Myocardial regulatory proteins and heart failure. European Journal of Heart Failure, 2006, 8, 333-342.	2.9	29
34	Troponin as a marker of myocardiac damage in drug-induced cardiotoxicity. Expert Opinion on Drug Safety, 2005, 4, 457-472.	1.0	64
35	Safety and tolerability of repeated administration of pyridoxal 2-chlorobenzoyl hydrazone in rabbits. Human and Experimental Toxicology, 2005, 24, 581-589.	1.1	12